<DOC>
	<DOCNO>NCT00773097</DOCNO>
	<brief_summary>The purpose study evaluate immune response MUC1 - poly-ICLC vaccine , investigational study vaccine . The MUC1 - poly-ICLC vaccine test person history advance adenomatous polyp , precursor colorectal cancer . The MUC1 - poly-ICLC vaccine develop prevent polyp advance colon cancer prevent polyp recur . MUC1 mucus normally present line human colon . However , MUC1 express large amount modify form adenomatous polyp colorectal cancer . These change MUC1 think part process progression adenomas toward cancer . The goal vaccine help immune system body identify change MUC1 accompany progression cancer eliminate abnormal cell make abnormal MUC1 .</brief_summary>
	<brief_title>Study MUC1 Peptide-Poly-ICLC Adjuvant Vaccine Individuals With Advanced Colorectal Adenoma</brief_title>
	<detailed_description>This phase II trial design assess antibody T cell response MUC1 vaccine among subject increase risk colorectal cancer virtue history advance adenoma . The primary objective evaluate immunogenicity combination 100mer MUC1 peptide adjuvant Poly-ICLC boost immune response MUC1 . Among secondary objective determine anti-MUC1 immunity , preexist vaccine induce , effect recurrence polyp . Subjects history advance adenoma recruit MUC1 vaccination . Vaccine administer week 0 , 2 , 10 . Some subject may pre-existing immunity MUC1 , account analytic phase . However , subject administer vaccine , regardless baseline antibody status . To insure accurate standardization measurement assessment antibody level , assay baseline antibody status do time response vaccine .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Age 40 70 year age . History follow condition ( operative note , endoscopy report , and/or pathology report must review locally confirm candidate meet least one follow entry criterion ) . 1 . Colorectal adenoma ( ) ≥ 1 cm maximal diameter 2 . Colorectal adenoma ( ) villous tubulovillous histology 3 . Colorectal adenoma ( ) highgrade dysplasia Willingness avoid pregnancy impregnate ( see ) period active study ( 1 year ) . ECOG performance status 0 1 Hemoglobin great 95 % low limit institutional normal . Platelets ≥100,000/µL . AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase , total bilirubin , BUN , creatinine ≤ 1.5x upper limit institutional normal . ANA &lt; 1:160 Receiving investigational agent . Presence active acute chronic infection History allergic reaction attribute compound similar chemical biologic composition study agent . History heritable cancer syndrome ( FAP , HNPCC ) Patients history autoimmune disease , restrict , inflammatory bowel disease , systemic lupus erythematosus , rheumatoid arthritis , ankylose spondylitis , scleroderma , multiple sclerosis . History malignancy &lt; 5 year prior Registration/Randomization evaluation , exclude nonmelanoma skin cancer . Any use oral corticosteroid ≤ 12 week prior Registration/Randomization . Current plan use immunomodulators include : Remicade , 6MP ( Mercaptopurine ) , Methotrexate , cyclosporine , immunomodulatory drug . Pregnant woman , teratogenic abortifacient effect study agent remain incompletely define . Breastfeeding woman , unknown potential risk adverse event nurse infant secondary treatment mother study agent .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Prevention</keyword>
	<keyword>Colorectal Cancer</keyword>
</DOC>